Physician profile
Susan E Bittenbender
NPI 1114988037
$1,945.50
in general payments reported to CMS, 2019-2025
21 companies · $725 in 2025
The $725 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $64.95 · 2021: $118 · 2022: $219 · 2023: $277 · 2024: $542 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $505.86 | 2020-2025 | Skyrizi |
| Janssen Biotech, INC. | $307.42 | 2022-2025 | Tremfya, Remicade, Stelara |
| Amgen INC. | $280.46 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $253.19 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $66.08 | 2021-2024 | Libtayo |
| Novartis Pharmaceuticals Corporation | $62.39 | 2021-2025 | |
| Galderma Laboratories, L.P. | $59.90 | 2022-2025 | Nemluvio, Aklief |
| Verrica Pharmaceuticals INC. | $55.71 | 2023-2024 | Ycanth |
| Sun Pharmaceutical Industries INC. | $47.60 | 2025 | |
| Genzyme Corporation | $42.17 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.39 | 2023-2025 | Spevigo |
| Incyte Corporation | $32.86 | 2022 | |
| Almirall LLC | $29.76 | 2025 | Klisyri |
| Organon LLC | $27.47 | 2025 | |
| Ucb, INC. | $25.97 | 2025 | Bimzelx |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21.67 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.49 | 2021 | |
| Genentech USA, INC. | $20.45 | 2024 | Erivedge |
| Dermira, INC. | $18.20 | 2020 | |
| Leo Pharma INC. | $14.60 | 2025 | Anzupgo |
| Journey Medical Corporation | $13.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Bittenbender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.